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Lots has been written on use of SSRI during pregnancy and possible short and long term negative outcomes on neonates. the
literature so far has described a various field of peripartum illness related to SSRI exposure during foetal life, such as increased
incidence of low birth weight, respiratory distress, persistent pulmonary hypertension, poor feeding, and neurobehavioural disease.
We know that different degrees of outcomes are possible, and not all the newborns exposed to SSRIs during pregnancy definitely will
develop a negative outcome. So far, still little is known about the possible etiologicmechanism that could not only explain the adverse
neonatal effects but also the degree of clinical involvement and presentation in the early period after birth. Pharmacogenetics
and moreover pharmacogenomics, the study of specific genetic variations and their effect on drug response, are not widespread.
This review describes possible relationship between SSRIs pharmacogenetics and different neonatal outcomes and summarizes the
current pharmacogenetic inquiries in relation to maternal-foetal environment.
1. Introduction
Selective serotonin reuptake inhibitors (SSRIs) are commonly
used antidepressants that act by inhibiting serotonin reuptake
in the synaptic cleft. Medications in this group include
fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram,
and escitalopram. At higher doses, paroxetine and sertraline
also block dopamine reuptake, which may contribute to their
antidepressant action. Venlafaxine is a combined serotonin-
norepinephrine reuptake inhibitor. Recently, multiple studies
have correlated SSRI use during pregnancy with adverse
neonatal effects, including neonatal respiratory distress, per-
sistent pulmonary hypertension, jaundice, feeding problems,
abnormal movements and tonus abnormalities, birth weight
below 10∘ centile, and even congenital cardiac disease (parox-
etine only). We know very well from the literature that
approximately 15% of all pregnant women have psychiatric
problems, in particular depression and anxiety [1, 2]; we
also know that the possible negative effects of untreated
psychiatric symptoms have to be compared and weighted
against the possible negative effects of medication during
pregnancy both in mother and foetus. The decision to treat
psychiatric disorders during pregnancy needs to be evaluated
in every single case and the literature has provided us with
many guidelines and reviews which can help in the daily
clinical practice [3–5] However, these position papers mainly
focus on the risk of foetal malformation and little is pro-
vided regarding the early neonatal outcomes of which every
neonatologist and pediatrician should be aware of. As we
understand the adverse foetal effects of specific psychotropic
medications, it is clear that not all fetuses exposed to a
givenmedicationwill show evidence of its associated possible
negative outcomes and that these effects may be varied in
both their presentation and timing.Therefore, the capacity to
identify foetal risk in an increasingly sensitive manner would
greatly benefit the specificity with which we will be able, as
physicians, to deal with possible negative neonatal outcomes.
This paper not only focuses on early neonatal outcome
after foetal exposure to a serotonin reuptake inhibitors drug
but also tries to investigate both the possible etiology of what
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is commonly called the poor neonatal adaptation and in par-
ticular what are the possible predictors of adverse outcome.
Our aim was to evaluate the current literature on this
topic, moreover investigating the possible correlation among
genes polymorphisms and different outcome in newborn
exposed to SSRI during foetal life. To the best of our know-
ledge only a few paper have focused on this topic.
2. Methods
We searched PubMed (2003–2013) using the key words SSRI
pharmacogenetics, newborn, and SSRI pharmacokinetics,
neonatal withdrawal syndrome combining them in couple
or triplets, producing several different search strategies. We
searched also for neonatal pharmacogenomics and preg-
nancy. Papers related to early neonatal outcomes and phar-
macogenetics of SSRI were acquired. More specifically we
aimed to evaluate the state of art so far regarding genotypic
correlation to adverse neonatal outcome in newborn exposed
to SSRI during foetal life. Inclusion criteria were identi-
fied maternal SSRI exposure during pregnancy, presence of
neonatal outcome assessment, and evaluation of molecu-
lar/genotypic influences on outcome. This search produced
more than 1500 publications, subsequently included publica-
tions were limited to meta-analyses, randomized controlled
trials, clinical trials, practice guidelines, reviews and case
report and in total 108 publications were selected. Among
these we excluded 79 publications because they did not meet
our criteria or because they did not include a significative
population sample. Finally we included in our review 36 pub-
lications. In our reference list we included other publications
which we thought to be of interest in the setting of the topic
debated.
Publications were excluded if
(i) non-English literature;
(ii) the publication did not address infant born of moth-
ers who had been treated with SSRI during preg-
nancy;
(iii) the publication did not address neonatal adverse
effects and among them were excluded publication
focused on malformative complications;
(iv) the publication did only address SSRI effects on
pregnant woman regardless of the newborn.
3. Discussion
Symptoms of poor neonatal adaptation are clearly related to
psychotropic drugs exposure during the whole trimesters of
pregnancy, but still the exact etiology is not fully understood.
A recent paper from Kievet et al. [6] stated three possible
explanation beyond the negative outcome in a newborn
from a depressed and on psychotropic treatment mother:
symptoms in newborn could be essentially caused by with-
drawal syndrome, since the psychotropic drugs will pass
through the placenta and therefore abrupt discontinuation
could lead to a spectrum of symptoms which easily mimic
the adult withdrawal syndrome. Another cause could be
drug toxicity, in which case symptoms may develop soon
after birth, due to drug plasma concentration higher than
the ones observed in newborn with withdrawal syndrome.
Third, it has been hypothesized that all psychotropic drugs
may act as intrauterine stressors and therefore they could
start foetal alteration in development, which could lead to
child’s behavior alteration at any age after birth. In with-
drawal syndrome symptoms occur soon after birth in a
range of time that goes approximately from 8 to 48 hours
after delivery; the most typical symptoms include feeding
difficulties, irritability, and tremors [7]. Sometimes newborn
can even present with sleeping difficulties, vomiting, and
hypo- or hypertonia. Respiratory distress can be common,
as previously documented its incidence can be significantly
higher in SSRI exposed neonates (13.9%) than the other
neonates [8]. Symptoms of drug toxicity can be partly similar
to symptoms of withdrawal, such as tremors and hypertonia.
However, the main difference is that in this condition symp-
toms occur immediately after birth, as in most cases plasma
concentration of psychotropic drugs are higher. Newborn can
present with irritability as well, and often hyperreflexia and
respiratory distress can be part of the spectrum. Since it can
be difficult to clearly distinguish withdrawal from toxicity it
has been hypothesized that a combination of both can be pos-
sible [9, 10], giving rise to a larger spectrum of clinical presen-
tation consisting of neurological, autonomic, gastrointestinal,
and respiratory symptoms. It is of extreme importance to
note that some newborn experience a mild presentation, for
example, with sleep disorders or gastrointestinal symptoms.
Some others instead present with more severe symptoms
such as neurological disorders, from tremors to convulsive
episodes or even with important respiratory distress. Many
studies reported that nearly 30% of all infants exposed to
SSRI during foetal life present with poor neonatal adaptation
[11, 12] and some of them described an increased incidence
of neonatal symptoms after exposure to paroxetine and
fluoxetine compared to other SSRIs [9, 13, 14]. On the basis
of adult-based extrapolation of SRI pharmacology we know
that the risk of withdrawal syndrome or toxicity seems to
be related to the half-life of SSRIs: the class agents with a
short half-life, such as paroxetine, are described to causemore
withdrawal symptoms that occur with declining drug levels.
Alternatively, exposure to long-life SSRIs like fluoxetine could
be more likely associated with neonatal toxicity syndrome,
with immediate onset of symptoms after birth [14]. Some
pharmacokinetic data support this [15, 16]: concentration of
fluoxetine seems to remain unchanged in infants between
delivery and the first 48 hours of life, while concentrations
of other SSRIs decrease even by 60% after the first 48 hours
of life, and among them paroxetine seems to be metabo-
lized most rapidly [17]. As already stated in the literature,
mechanisms that clearly explain why only some infants who
have been exposed to maternal use of SSRIs during foetal life
present with poor adaptation after birth are still unknown.
It is now well known that the serotonin transporter 5HTT
plays an important role as a regulator of serotoninergic
neurotransmission and modifier of SSRIs effects: differences
in transporter-dependant reuptake efficiency are related to
insertion/deletion polymorphism in the promoter region of
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Table 1: Principal papers which focused on the role of genotypes and possible neonatal outcomes.
Laine et al., 2004
[20]
32-year-old woman
SSRI exposed
Chlorpromazine,
paroxetine
Genetic analysis: CYP2D6∗4 mutation in both alleles = poor metabolizer
APGAR 7/8/9
Poorly reactive, respiratory distress, tremors, hypotonia, and hypoglycemia
Oberlander et al.,
2008 [19]
37 women SSRI
exposed versus 47
nonexposed
Paroxetine,
fluoxetine,
sertraline,
venlafaxine,
citalopram
SS alleles: lower 5min APGAR score (reduced respiratory effort)
LL alleles: lower birth weight
Hilli et al., 2009
[22]
20 women SSRI
exposed during
pregnancy and
lactation
Citalopram
Fluoxetine
No differences between 5HTT and 5HT receptors genotypes and
serotoninergic symptoms scores.
Higher scores in infants with two high activity alleles of the MAO-A
polymorphism and rapid CYP2DS metabolizers.
Table 2: Genotypes as possible regulators of perinatal serotoninergic symptoms after in utero exposure to SSRIs—courtesy of Oberlander
2008—Molecular Psychiatry. Infant outcomes and SLC6A4 genotype: means (s.d.).
SLC6A4 genotype
ll ls ss
No exposure
(𝑛 = 14)
SRI exposure
(𝑛 = 14)
No exposure
(𝑛 = 22)
SRI exposure
(𝑛 = 16)
No exposure
(𝑛 = 11)
SRI exposure
(𝑛 = 7)
Duration of prenatal SRI
exposure (days) NA 240 (57) NA 206 (92) NA 231 (62)
Maternal mean daily dose of
medication (𝑧 scorea) NA 0.181 (0.138) NA 0.299 (0.283) NA 0.153 (0.101)
Gestational age at birth (weeks) 39.8 (1.45) 39.4 (1.48) 40.3 (1.03) 39.3 (1.61) 40.3 (1.09) 39.4 (1.44)
Birth weight (g) 3583 (594) 3416 (509) 3691 (455) 3239 (549)∗ 3465 (545) 3763 (367)
Birth length (cm) 52.3 (3.80) 50.1 (2.27) 51.9 (2.70) 50.5 (2.42) 52.3 (2.40) 53.1 (2.28)
Head circumference (cm) 34.8 (1.49) 34.3 (1.34) 35.2 (1.28) 34.5 (1.17) 35.0 (1.14) 35.2 (1.68)
Length of newborn stay in hospitals (h) 51.0 (22.2) 61.3 (27.9) 48.6 (25.6) 61.3 (40.9) 46.9 (27.6) 62.1 (21.4)
NA: not applicable; SRI: serotonin reuptake inhibitors. 𝑃 < 0.05 for differences between exposures and nonexposure within genotypes. aA composite drug
dosage “𝑧 score” was tabulated for drug dosage to account for multiple drugs each with varying drug dose ranges.
the SLC6A4 gene, thus leading to different transporter gene
expression and clinical differences in SSRI efficacy [18]. To
the best of our knowledge so far only three papers have
investigated the possible relationship between genotypes and
possible adverse outcome, as shown in Table 1.
An interesting paper from Oberlander et al. [19] sought
to investigate whether neonatal effects of SSRIs are related to
genotypes for the serotonin transporter (SLC6A4) promoter;
specifically, whether affected neonates were carriers of the
short or long SLC6A4 alleles. The study suggested that
prenatal SSRI exposure was associated with adverse neonatal
outcomes and these effects weremoderated by infant SLC6A4
genotypes. More specifically risk of respiratory symptoms
was higher in neonates exposed to SSRI in utero who had the
long genotypes, compared to nonexposed neonates. More-
over, the relationships between polymorphisms and specific
outcomes varied during the neonatal period, suggesting
that beyond apparent gene-medication interactions, multiple
mechanisms contribute to the adverse neonatal outcomes
after prenatal SSRI exposure; see Tables 2 and 3.
Prenatal serotonin reuptake inhibitor exposure is com-
mon and neonatal outcomes vary greatly, often leading to
confusion about whether to use or even continue antenatal
use of these antidepressants. Importantly, some but not
all infants are affected, which raises questions about how
maternal drugmetabolism contributes to fetal drug exposure.
To address this question, here we briefly review the role of
maternal, fetal, and placental genetic factors that affect the
extent of fetal drug exposure.
3.1. Genetic Factors Affecting Infant Exposure to SSRIs. An
interesting study fromLaine et al. [20] in 2004 reported a case
of a newborn who experienced severe complications after
birth and the severity of these symptoms was significantly
associated with the low cord blood 5-hydroxyindoleacetic
acid concentrations, a marker for serotonin turnover, but
not with infant plasma drug levels, thus suggesting that the
perinatal sequelaewere related to high central nervous system
serotonin activity rather than discontinuation syndrome. At
the molecular analyses this newborn was found to be a
carrier of two defective CYP2D6 alleles, resulting in inactive
CYP2D6 enzyme. In this respect, the SSRI drug plasma level
in newborn can be surprisingly low, even if the neonates
presents with serotoninergic symptoms which can easily
mimic a withdrawal syndrome—Table 4; despite the low
plasma concentrations of SSRI drug, the absence of CYP2D6
in the central nervous system could have caused high drug
concentrations at the effector site, leading to strong serotonin
reuptake inhibition and serotoninergic overstimulation in the
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Table 3: Genotypes as possible regulators of perinatal serotoninergic symptoms after in utero exposure to SSRIs—courtesy of Oberlander
2008—Molecular Psychiatry. Frequency (%) of PNA symptoms by SLC6A4 genotype and SRI exposure.
SLC6A4 genotype
ll ls ss
No exposure
(𝑛 = 14)
SRI exposure
(𝑛 = 14)
No exposure
(𝑛 = 22)
SRI exposure
(𝑛 = 16)
No exposure
(𝑛 = 11)
SRI exposure
(𝑛 = 7)
Tachycardia (>160 bpm) 14.3 57.1 13.6 25.0 27.3 14.3
Bradycardia (<100 bpm) 7.1 0.0 4.5 0.0 0.0 0.0
Tachypnea breathing (>60min) 14.3 57.1∗ 13.6 25.0 27.3 14.3
Respiratory distress 14.3 50.0∗ 9.1 43.8 9.1 42.9
Itteriness 0.0 35.7∗ 9.1 25.0 9.1 57.1∗
Increased motor tone 0.0 14.3 0.0 0.0 0.0 42.9∗
Hypoglycemia (<3.3mmol/L) 7.1 21.4 9.1 25.0 9.1 14.3
Hyperglycemia (>7mmol/L) 0.0 7.1 0.0 0.0 0.0 14.3
PNA: poor neonatal adaptation; SRI: serotonin reuptake inhibitors. ∗Compared with no exposure on Pearson’s 𝜒2 (all 𝑃 < 0.05).
Table 4: Neonatal symptoms possibly caused by SSRI withdrawal or toxicity.
Neurological Tremor, hyper/hypotonicity/jitteriness, and convulsions
Restlessness, apathy, abnormous cry, and abnormal sleep
Gastrointestinal Diarrhoea, vomiting, and breast feeding problems
Autonomic Temperature instability, increased sweating, and fever, and blood pressure and heart rate changes
Endocrine Jaundice and hypoglycaemia
Respiratory Respiratory distress, tachypnoea, and desaturation
infant; therefore, from a clinical-practical point of view it
is once more important to keep in mind that the so-called
serotoninergic symptoms are sometimes indistinguishable
from SSRI withdrawal.
Similarly to what happens withmaternal opiate exposure,
signs of intoxication can present immediately and dissipate
over a matter of hours, whereas withdrawal may take days
or weeks to resolve. This is indirectly supported by opposite
findings describing a case of a baby born from parents cate-
gorized as extensive metabolizers according to their CYP2D6
genotype who experienced an episode of SSRI withdrawal
reaction, although he was not at an increased genetic risk of
drug accumulation. Taken together, these cases suggest that
withdrawal may account for the abnormal clinical findings in
these patients. Additionally, as underlined by Stiskal [21] the
differential diagnosis between SSRI neonatal withdrawal and
serotoninergic symptoms is not merely theoretical. Indeed a
withdrawal should be optimally treated with SSRI, whereas
such treatment may endanger babies exhibiting serotoniner-
gic syndrome.
Further evidence regarding the importance of genotypic
patternwas added in 2009with a controlled prospective study
from Hilli et al. [22] who were the first to investigate the
relationship between relevant genetic polymorphisms and
monoamine concentrations in newborn who were exposed
to SSRI during late pregnancy; they found that rapidMAO-A
metabolizers had higher scores for perinatal serotoninergic
symptom and therefore suggested that MAO-A genotype
could be an independent risk factor for occurrence and sever-
ity of perinatal serotoninergic symptoms after pregnancy
exposure to SSRI.
Recent studies have illustrated the importance of pla-
cental drug transport proteins, such as P-glycoprotein (Pgp)
and breast cancer resistance protein (BCRP) in limiting fetal
exposure to drugs and toxins. Moreover, increasing evidence
supports a role for Pgp and BCRP in the normal development
and physiological function of the placenta. Several single
nucleotide polymorphisms (SNPs) in the genes encoding
Pgp and BCRP have been described and are associated with
altered protein expression, transporter activity, and clinical
outcome in studies focusing on tissues other than the placenta
[23]. To date, evidence suggests that SNPs in both ABCB1
and ABCG1 can alter expression of their respective protein;
however, the functional significance of these polymorphisms
in regulating the placental transfer of SSRI is not clear. Indeed,
consistent evidence is available showing that polymorphisms
in ABC drug efflux transporters significantly affected SSRI
exposure. However, studies specifically dealing with preg-
nancy outcome are lacking.
Inmore details to the best of our knowledge the first paper
to describe a possible association between ABCB1 variants
with SSRIs responsewas the interesting paper fromKato et al.,
[24] which examined the possible association of 3 functional
ABCB1 polymorphisms (C3435T: rs1045642, G2677T/A:
rs2032582, c1236t: RS1128503) with response to paroxetine in
a Japanese major depression sample cohort. In their results
they showed a significant association of the nonsynonymous
single nucleotide polymorphism G2677T/A with a treatment
response to paroxetine; furthermore, the wild variants haplo-
type resulted are associated with poor response.
On respect of this topic, another paper from de Klerk
et al. [25] studied the possible association of ABCB1 gene
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variants with adverse effects of SSRIs which among the
antidepressants show a major affinity as substrate for P-
glycoprotein. In their cohort of 424 depressed patients they
found a significant association between the number of SSRI-
related adverse drug effects and two single variants and one
haplotype of the gene.They concluded that the serotoninergic
effects were significantly predicted by these variants and
haplotype, therefore, two common polymorphisms of the
ABCB1 gene.
3.2. Factors Affecting Infants Exposure to SSRI through Breast
Milk. The treatment of breastfeeding mothers with depres-
sion raises several dilemmas, including the possible risk of
drug exposure through breast milk for the infant against
the disadvantage of not receiving mother’s milk. [26]. As
for SSRIs, evidence is available showing that detectable drug
levels have been found in breast milk for all antidepressant
studies. In general, drug concentrations inmilk parallel those
in maternal plasma, but with a slight delay.
Only a few and inconclusive studies have explored the role
of genetic background on exposure of infants to SSRI though
milk lactation. In their study of 25 breastfeedingmothers who
were treated with citalopram, sertraline, paroxetine, fluox-
etine, and venlafaxine, Berle et al. [27] evaluated multiple
variations in maternal CYP2D6 and CYP2C19 genotypes,
including genotypes associated with “poor metabolizing.”
They found that no specific genotypes correlated with vari-
ations in excreted medications in breast milk and all of the
infant’s serum levels were either undetectable or low.
Taking all current knowledge into considerations it has
been recently suggested that when antidepressant treatment
is indicated in women with postpartum depression, they
should generally not be advised to continue breastfeeding. If
this is not pursuable, among the different SSRIs, paroxetine
and sertraline are most likely suitable first-line agents due
to their low excretion in milk. However, an individual risk-
benefit assessment should always be performed.
3.3. Genetic Factors Affecting Maternal Exposure to SSRI
during Pregnancy. Ververs et al. [28] examined the changes
of maternal paroxetine concentrations during pregnancy
in relation to cytochrome P450 (CYP) 2D6 genotype/pheno-
type. These authors reported that women who were geno-
typed as extensivemetabolizers or ultrarapidmetabolizers for
CYP2D6 showed steadily decreasing plasma paroxetine con-
centrations during the course of pregnancy, with a decrease
of 0.3mg/L for each week of pregnancy. In contrast, plasma
paroxetine concentrations of intermediate metabolizers and
poor metabolizers increased during pregnancy, resulting
in an increase of 0.82mg/L for each week of pregnancy.
Interestingly, in extensive/ultrarapidmetabolizers the depres-
sive symptoms increased significantly during the course
of pregnancy, while in the intermediate/poor metabolizer
groups these did not change. According to the latter find-
ings, accumulation of paroxetine in a considerable group of
pregnant womenmay lead to unintended increased exposure
of paroxetine to the unborn child. Although not formally
proven by ad hoc studies, it can be reasonably speculated
that the same could apply also for other SSRIs, being mainly
metabolized not only by CYP2D6 but also by CYP2C19,
CYP3A, and CYP1A2 which in turn are encoded by highly
polymorphic genes. Accordingly, it could be reasonably
hypothesized that monitoring exposure of pregnant women
to SSRI through pharmacogenetic approaches or through
therapeutic monitoring of plasma SSRI concentrations may
favor the early identifications of women at risk which could
potentially beneficiate from drug dose adjustments [29].
The state of the art so far describes a small pattern
of studies that are relevant in their potential impact of
predicting possible adverse outcomes depending on genetic
variants, and ourwish is that further studies will be developed
in the maternal-neonatal field, in order to implement the
knowledge and possible clinical implications regarding foetal
outcome and newborn health. A better understanding of
these polymorphisms will allow prediction of when normal
placental physiology could be altered and lead to the devel-
opment of appropriate preventive therapies, in summary a
full understanding of which SNPs affect placental expression
and function would be useful for predicting altered foetal
exposure to drugs.
4. Conclusion
Approximately 7–13% of infants born in the United States
each year are exposed to maternal major depressive disorder
during gestation and an estimated 7.6%of all pregnantwomen
take an antidepressant. Because of their low side effect profiles
and relatively low risk on the foetus, among antidepressants
SSRIs are a current first-line choice for pharmacologic treat-
ment during pregnancy, even due to the well-known fact that
exposure to maternal depression in utero has been already
linked to adverse neurobehavioural development.
We know that the placenta is the key regulatory organ
which maintains foetal homeostasis; therefore, we strongly
think that it is the critical site to examine if we want to early
detect alterations in neurotransmitter or genetic variations
which could potentially be involved in dysregulation of the
intrauterine environment and therefore foetal development.
These studies account for a strong clinical relevance when
limiting foetal exposure to potential teratogens or when drug
delivery to the foetus is warranted for therapeutic effects, as
in the case of maternal depression.
When certain genetic variations can be linked with spe-
cific foetal/neonatal outcomes, individual gene sequencing
may provide more knowledge for a safe maternal phar-
macotherapies on an individualized basis and therefore
contributing to better stratify the risk for possible adverse
neonatal outcome. The development and application of
this field could offer greater potential to better institute
appropriate medical care but obviously raises some concerns
about feasibility in daily clinical practice. Although research
in the area of drug metabolism in pregnancy is rapidly
evolving, physicians are often limited by lack of knowledge of
pathophysiological mechanisms that link a specific drug and
adverse outcomes, and we think that research in maternal-
foetal-neonatal pharmacogenomics will undoubtedly not
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only improve our overall understanding but also help us to
stratify patients based on individual risk.
Further studies must be considered, in order to better
clarify the role of haplotypes, environmental factors, and
comorbidities, both to avoid and predict possible clinical
adverse outcomes on newborns from depressed mothers.
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